|
|
||||||||
Department of Physiology and Biochemistry, School of Medicine, University of São Paulo, 14049-900 Ribeirão Preto, São Paulo, Brazil
The role of adrenoceptor
subtypes and of cAMP on rat skeletal muscle proteolysis was
investigated using a preparation that maintains tissue glycogen stores
and metabolic activity for several hours. In both soleus and extensor
digitorum longus (EDL) muscles, proteolysis decreased by 15-20%
in the presence of equimolar concentrations of epinephrine,
isoproterenol, a nonselective
-agonist, or clenbuterol, a selective
2-agonist. Norepinephrine also reduced proteolysis but
less markedly than epinephrine. No change in proteolysis was observed
when muscles were incubated with phenylephrine, a nonselective
-agonist. The decrease in the rate of protein degradation induced by
10
4 M epinephrine was prevented by 10
5 M
propranolol, a nonselective
-antagonist, and by 10
5 M
ICI 118.551, a selective
2-antagonist. The
antiproteolytic effect of epinephrine was not inhibited by prazosin or
yohimbine (selective
1-and
2-antagonists,
respectively) or by atenolol, a selective
1-antagonist.
Dibutyryl cAMP and isobutylmethylxanthine reduced proteolysis in both
soleus and EDL muscles. The data suggest that catecholamines exert an
inhibitory control of skeletal muscle proteolysis, probably mediated by
2-adrenoceptors, with the participation of a
cAMP-dependent pathway.
epinephrine; clenbuterol; dibutyryl cAMP; isobutylmethylxanthine; protein degradation
This article has been cited by other articles:
![]() |
G. S. Lynch and J. G. Ryall Role of {beta}-Adrenoceptor Signaling in Skeletal Muscle: Implications for Muscle Wasting and Disease Physiol Rev, April 1, 2008; 88(2): 729 - 767. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Baviera, N. M. Zanon, L. C. Carvalho Navegantes, R. H. Migliorini, and I. d. C. Kettelhut Pentoxifylline inhibits Ca2+-dependent and ATP proteasome-dependent proteolysis in skeletal muscle from acutely diabetic rats Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E702 - E708. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. O. Kline, F. J. Panaro, H. Yang, and S. C. Bodine Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol J Appl Physiol, February 1, 2007; 102(2): 740 - 747. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Busquets, M. T. Figueras, G. Fuster, V. Almendro, R. Moore-Carrasco, E. Ametller, J. M. Argiles, and F. J. Lopez-Soriano Anticachectic Effects of Formoterol: A Drug for Potential Treatment of Muscle Wasting Cancer Res., September 15, 2004; 64(18): 6725 - 6731. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. C. Navegantes, N. M. Z. Resano, A. M. Baviera, R. H. Migliorini, and I. C. Kettelhut Effect of sympathetic denervation on the rate of protein synthesis in rat skeletal muscle Am J Physiol Endocrinol Metab, April 1, 2004; 286(4): E642 - E647. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. C. Navegantes, N. M. Z. Resano, R. H. Migliorini, and I. C. Kettelhut Catecholamines inhibit Ca2+-dependent proteolysis in rat skeletal muscle through {beta}2-adrenoceptors and cAMP Am J Physiol Endocrinol Metab, September 1, 2001; 281(3): E449 - E454. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Clanton and P. F. Klawitter Physiological and Genomic Consequences of Intermittent Hypoxia: Invited Review: Adaptive responses of skeletal muscle to intermittent hypoxia: the known and the unknown J Appl Physiol, June 1, 2001; 90(6): 2476 - 2487. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |